Afuco™ Anti-Human GD2 ADCC Recombinant Antibody (hu14.18K322A), ADCC Enhanced (CAT#: AFC-291CL)

Figure 1 Predicted (blue line) and average predicted (gold line) hu14.18K322A serum levels for 11 patients treated at 60 mg/m2 (maximum-tolerated dose) based on two-compartment model.

Blue dots represent observed hu14.18K322A serum levels for representative patient who had median body-surface area among patients treated at 60 mg/m2. Peak serum level on day 4 (immediately after four daily infusions) was greater than that after first infusion on day 1. Elimination of agent after peak on day 1 showed similar pattern to that seen after peak on day 4.

Navid,F.,Sondel,P.M.,Barfield,R.,Shulkin,B.L.,Kaufman,R.A.,Allay,J.A.,& Goldberg, J. (2014).Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14. 18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. Journal of clinical oncology, 32(14), 1445.

Figure 2 Anti-GD2 nanoconstructs are highly specific for GD2 molecules on neuroblastoma cells.

(A) Flow cytometry of anti-GD2-BNF (aGD2-BNF) binding to GD2+ neuroblastoma cells, evidenced by fluorescent antihuman IgG (ahu IgG) antibody (tinted histograms), compared with cells treated with ahu IgG antibody alone (heavy contour clear histograms) or cell autofluorescence (autofluor, light contour clear histograms). (B) Flow cytometry of anti-GD2-BNF or anti-GD2 hu14.18K322A alone binding to GD2+ CHLA-20 cells. (C) Immunofluorescence microscopy (400×) of CHLA-20 detecting human IgG (hu IgG) and nuclear DAPI. Cells were pretreated with BNF, anti-GD2-BNF, hu IgG or medium only (upper four panels). Pretreatment with 1A7 anti-idiotype antibody (aID) or with 14.G2a anti-GD2 antibody (aGD2–14.G2a) prevents binding of anti-GD2-BNF to cells (lower two panels).

Baiu,D.C.,Artz, N.S.,McElreath,M.R.,Menapace,B.D.,Hernando,D. Reeder,S.B.,& Otto,M.(2015).High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine, 10(19),2973-2988.

Figure 3 Iron is targeted to GD2+ neuroblastoma cells after anti-GD2-Bionized NanoFerrite treatment.

(A) Ferrozine spectrophotometry shows increase in Fe2+/Fe3+ in GD2+ cells after anti-GD2-BNF (aGD2-BNF) treatment when compared with basal iron levels. Averages ± standard error of three to five experiments per cell line p = 0.01). (B) Ferrozine spectrophotometry shows pretreatment of CHLA-20 cells with free hu14.18K322A anti-GD2 antibody (aGD2) prevents cell loading with iron during anti-GD2-BNF treatment. Averages ± standard error of four experiments (p ≤ 0.04; p = 0.01). (C) Microscopy of Perls staining of nonheme iron in CHLA-20 cells after treatment with untargeted BNF, targeted anti-GD2-BNF and free hu14.18K322A anti-GD2 antibody (aGD2) pretreatment before anti-GD2-BNF. Representative of five repeats, 200×.

Baiu,D.C.,Artz, N.S.,McElreath,M.R.,Menapace,B.D.,Hernando,D. Reeder,S.B.,& Otto,M.(2015).High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine, 10(19),2973-2988.